Abstract
Background CT perfusion (CTP) has been suggested to increase the rate of large vessel occlusion (LVO) detection in patients suspected of acute ischemic stroke (AIS) if used in addition to a standard diagnostic imaging regime of CT angiography (CTA) and non-contrast CT (NCCT). The aim of this study was to estimate the costs and health effects of additional CTP for endovascular treatment (EVT)-eligible occlusion detection using model-based analyses.
Methods In this Dutch, nationwide retrospective cohort study with model-based health economic evaluation, data from 701 EVT-treated patients with available CTP results were included (January 2018–March 2022; trialregister.nl:NL7974). We compared a cohort undergoing NCCT, CTA, and CTP (NCCT+CTA+CTP) with a generated counterfactual where NCCT and CTA (NCCT+CTA) was used for LVO detection. The NCCT+CTA strategy was simulated using diagnostic accuracy values and EVT effects from the literature. A Markov model was used to simulate 10-year follow-up. We adopted a healthcare payer perspective for costs in euros and health gains in quality-adjusted life years (QALYs). The primary outcome was the net monetary benefit (NMB) at a willingness to pay of € 80,000, secondary outcomes were the difference between LVO detection strategies in QALYs (Δ QALY) and costs (Δ Costs).
Results We included 701 patients (median age:72 IQR:[62-81]) years). Per LVO patient, CTP-based occlusion detection resulted in cost savings (Δ Costs median:€ -2671 IQR:[€ -4721;€ -731]), a health gain (Δ QALY median:0.073 IQR:[0.044;0.104]), and a positive NMB (median:€ 8436 IQR:[5565;11876]) per LVO patient.
Conclusion Adding CTP to NCCT and CTA for EVT-eligible LVO detection resulted in cost savings and health gains.
Clinical relevance statement In recent clinical trials, CTP-based patient selection for endovascular treatment resulted in worse patient outcomes after ischemic stroke. We found that an alternative use of CTP, CTP-based screening for endovascular treatable occlusions is cost-effective.
Key points
Using CTP to detect an endovascular treatment-eligible occlusions resulted in a health gain and cost savings when considering 10-years of follow-up.
Depending on the screening costs related to the number of patients needed to image (NNI) with CTP, cost savings could be considerable (Δ Costs NNI=4.3 median:€ -3857 IQR:[€ -5907;€ - 1916]; NNI=8.3 median:€ -2671 IQR:[€ - 4721;€ -731])
Variations in sensitivity difference due to the use of CTP affect the health gain (Δ QALYs sensitivity difference=baseline median:0.073 IQR:[0.044;0.104]; sensitivity difference=(baseline-4%) median:0.052 IQR:[0.031;0.075]).
Competing Interest Statement
Disclosures and conflicts of interest BJE reports grants from LtC (ZonMW and TKI-PPP of Health Holland). WHvZ reports personal fees from Codman and from Stryker. DWJD report grants from the Dutch Heart Foundation, AngioCare, Medtronic/Covidien/EV3, MEDAC/LAMEPRO, Penumbra, Top Medical/Concentric, Stryker, and Cerenovus; consultation fees from Stryker, Bracco Imaging, and Servier, received by the Erasmus University Medical Centre outside this project. CBLMM reports grants from TWIN, during the conduct of the study and grants from CVON/Dutch Heart Foundation, European Commission, Dutch Health Evaluation Program, and from Stryker outside this project (paid to institution) and is shareholder of Nicolab. AJY reports Research grants from Medtronic, Cerenovus, Penumbra, Stryker, and Genentech. Consultant for Penumbra, Cerenovus, Nicolab, Philips, Vesalio, Zoll Circulation, and NIH/NINDS. YR is a shareholderof Nicolab. Equity interests in Insera Therapeutics and Nicolab. All other contributors report no conflicts of interest.
Clinical Protocols
https://journals-sagepub-com.stanford.idm.oclc.org/doi/full/10.1177/23969873221092535
Funding Statement
Funding statement The CLEOPATRA healthcare evaluation study was funded by Leading the Change (LtC). LtC is financed by Zorgverzekeraars Nederland (ZN) and supports various healthcare evaluations in the Netherlands as part of the Healthcare Evaluation Netherlands project. LtC was not involved in the study design, monitoring, data collection, statistical analyses, interpretation of results, or manuscript writing, but the progress of the study was continuously monitored by LtC. The MR CLEAN-NO IV trial (ISRCTN80619088) and MR CLEAN-MED trial (ISRCTN76741621) were part of the Collaboration for New Treatments of Acute Stroke (CONTRAST) consortium. The CONTRAST consortium acknowledges the support from the Netherlands Cardiovascular Research Initiative, an initiative of the Dutch Heart Foundation (CVON2015-01: CONTRAST), and from the Brain Foundation Netherlands (HA2015.01.06). The collaboration project is additionally financed by the Ministry of Economic Affairs by means of the PPP Allowance made available by the Top Sector Life Sciences & Health to stimulate public-private partnerships (LSHM17016). This work was funded in part through unrestricted funding by Stryker, Medtronic and Cerenovus. The funding sources were not involved in study design, monitoring, data collection, statistical analyses, interpretation of results, or manuscript writing.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Patient inclusion was in adherence with the declaration of Helsinki and was subject to an ethical board review. The CLEOPATRA study protocol has been reviewed by the Amsterdam UMC ethical review board and was waived for informed consent (Amsterdam UMC reference: W19_281#19.334). Retrospective, large-scale, observational studies do not fall under the Medical Research Involving Human Subjects Act (WMO). For patients included in the MR CLEAN-NO IV (ISRCTN80619088, registered 31 October 2017), and MR CLEAN MED (ISRCTN76741621, registered 7 December 2017) trials informed consent has been received previously. The ethical review board of the Erasmus MC has waived the requirement for informed consent for patients included in the MR CLEAN Registry (internal reference Erasmus MC: MEC-2014-235, 27 August 2014).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data will be made available upon reasonable request. Specific access can be granted through a secure environment.
Abbreviations
- AIS
- Acute ischemic stroke
- EVT
- Endovascular treatment
- ICA
- internal carotid artery
- ICA-T
- terminus of ICA
- ICER
- Incremental cost-effectiveness ratio
- IQR
- Interquartile range
- NMB
- Net monetary benefit
- NNI
- Number needed to image
- PSA
- Probabilistic sensitivity analysis
- QALY
- Quality-adjusted life year
